Journal Mobile Options
Table of Contents
Vol. 126, No. 4, 2001
Issue release date: December 2001
Int Arch Allergy Immunol 2001;126:267–276
(DOI:10.1159/000049523)

Interleukin 13: A Growth Factor in Hodgkin Lymphoma

Skinnider B.F. · Kapp U. · Mak T.W.
aAmgen Institute, Ontario Cancer Institute and the Departments of Medical Biophysics and Immunology, University of Toronto, Toronto, Canada, bDepartment of Hematology/Oncology, University Medical Center, Freiburg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Classical Hodgkin lymphoma (cHL) is a malignant disorder of lymph nodes with distinctive clinical and pathologic features. These features are thought to be primarily due to the abnormal production of multiple cytokines by the malignant cell population of HL, the Reed-Sternberg (RS) cells. We have previously demonstrated that interleukin (IL)-13 expression is a common feature of HL and have studied its role as an autocrine growth factor for RS cells. IL-13 and IL-13Rα1, the IL-13-specific receptor chain, are frequently expressed by HL-derived cell lines and by RS cells from biopsy material of tissues involved by HL. Neutralization of IL-13 in cultures of the HL-derived cell lines HDLM-2 and L-1236 leads to a dose-dependent inhibition of proliferation, and is associated with increased apoptosis in L-1236 cells. Signal transducer and activator of transcription (STAT) 6 is an important mediator of IL-13 signaling. STAT6 is constitutively activated in HL cell lines due to autocrine secretion of IL-13. STAT6 is also phosphorylated (P-STAT6) in RS cells from many primary HL samples, supporting the hypothesis that IL-13 signaling occurs in these malignant cells in vivo. Coexpression of IL-13, IL-13Rα1 and P-STAT6 is uncommon in non-Hodgkin lymphomas. Following a description of the clinical and pathologic features of HL, this review will discuss the function of IL-13 as an autocrine growth factor for RS cells in HL and its potential role in mediating other features of this disease.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Diehl V, Mauch P, Harris NL: Hodgkin’s disease; in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott Williams & Wilkins, 2001.
  2. Kuppers R, Rajewsky K: The origin of Hodgkin and Reed/Sternberg cells in Hodgkin’s disease. Annu Rev Immunol 1998;16:471–493.
  3. Muschen M, Rajewsky K, Brauninger A, Baur AS, Oudejans JJ, Roers A, Hansmann ML, Kuppers R: Rare occurrence of classical Hodgkin’s disease as a T cell lymphoma. J Exp Med 2000;191:387–394.
  4. Drexler HG: Recent results on the biology of Hodgkin and Reed-Sternberg cells. II. Continuous cell lines. Leuk Lymphoma 1993;9:1–25.
  5. Kanzler H, Hansmann ML, Kapp U, Wolf J, Diehl V, Rajewsky K, Kuppers R: Molecular single cell analysis demonstrates the derivation of a peripheral blood-derived cell line (L1236) from the Hodgkin/Reed-Sternberg cells of a Hodgkin’s lymphoma patient. Blood 1996;87:3429–3436.
  6. Drexler HG: Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymphoma 1992;8:283–313.

    External Resources

  7. Kapp U, Yeh WC, Patterson B, Elia AJ, Kagi D, Ho A, Hessel A, Tipsword M, Williams A, Mirtsos C, Itie A, Moyle M, Mak TW: Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J Exp Med 1999;189:1939–1946.
  8. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U, Patterson B, Snow BE, Mak TW: Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2001;97:250–255.
  9. Zurawski G, de Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994;15:19–26.
  10. de Waal Malefyt R, Abrams JS, Zurawski SM, Lecron JC, Mohan-Peterson S, Sanjanwala B, Bennett B, Silver J, de Vries JE, Yssel H: Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int Immunol 1995;7:1405–1416.
  11. Kindler V, Matthes T, Jeannin P, Zubler RH: Interleukin-2 secretion by human B lymphocytes occurs as a late event and requires additional stimulation after CD40 cross-linking. Eur J Immunol 1995;25:1239–1243.

    External Resources

  12. McKenzie AN, Culpepper JA, de Waal Malefyt R, Briere F, Punnonen J, Aversa G, Sato A, Dang W, Cocks BG, Menon S, de Vries JE, Banchereau J, Zurawski G: Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc Natl Acad Sci USA 1993;90:3735–3739.
  13. Defrance T, Carayon P, Billian G, Guillemot JC, Minty A, Caput D, Ferrara P: Interleukin 13 is a B cell stimulating factor. J Exp Med 1994;179:135–143.
  14. Lomo J, Blomhoff HK, Jacobsen SE, Krajewski S, Reed JC, Smeland EB: Interleukin-13 in combination with CD40 ligand potently inhibits apoptosis in human B lymphocytes: Upregulation of Bcl-xL and Mcl-1. Blood 1997;89:4415–4424.

    External Resources

  15. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, Labit C, Leplatois P, Liauzun P, Miloux B, Minty C, Casellas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993;362:248–250.
  16. de Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, Dang W, Zurawski G, de Vries JE: Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993;151:6370–6381.
  17. Graber P, Gretener D, Herren S, Aubry JP, Elson G, Poudrier J, Lecoanet-Henchoz S, Alouani S, Losberger C, Bonnefoy JY, Kosco-Vilbois MH, Gauchat JF: The distribution of IL-13 receptor alpha1 expression on B cells, T cells and monocytes and its regulation by IL-13 and IL-4. Eur J Immunol 1998;28:4286–4298.
  18. Bonecchi R, Sozzani S, Stine JT, Luini W, D’Amico G, Allavena P, Chantry D, Mantovani A: Divergent effects of interleukin-4 and interferon-gamma on macrophage-derived chemokine production: An amplification circuit of polarized T helper 2 responses. Blood 1998;92:2668–2671.
  19. Andrew DP, Chang MS, McNinch J, Wathen ST, Rihanek M, Tseng J, Spellberg JP, Elias CG 3rd: STCP-1 (MDC) CC chemokine acts specifically on chronically activated Th2 lymphocytes and is produced by monocytes on stimulation with Th2 cytokines IL-4 and IL-13. J Immunol 1998;161:5027–5038.

    External Resources

  20. Hoeck J, Woisetschlager M: STAT6 mediates eotaxin-1 expression in IL-4 or TNF-alpha-induced fibroblasts. J Immunol 2001;166:4507–4515.
  21. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A: Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998;187:875–883.
  22. Kitaura M, Nakajima T, Imai T, Harada S, Combadiere C, Tiffany HL, Murphy PM, Yoshie O: Molecular cloning of human eotaxin, an eosinophil-selective CC chemokine, and identification of a specific eosinophil eotaxin receptor, CC chemokine receptor 3. J Biol Chem 1996;271:7725–7730.
  23. Luttmann W, Matthiesen T, Matthys H, Virchow JC Jr: Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-α on eosinophil activation in vitro. Am J Respir Cell Mol Biol 1999;20:474–480.
  24. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999;103:779–788.
  25. Chiaramonte MG, Donaldson DD, Cheever AW, Wynn TA: An IL-13 inhibitor blocks the development of hepatic fibrosis during a T-helper type 2-dominated inflammatory response. J Clin Invest 1999;104:777–785.
  26. Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ: cDNA cloning and characterization of the human interleukin 13 receptor α chain. J Biol Chem 1996;271:29265–29270.
  27. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE: The IL-4 receptor: Signaling mechanisms and biologic functions. Annu Rev Immunol 1999;17:701–738.
  28. Caput D, Laurent P, Kaghad M, Lelias JM, Lefort S, Vita N, Ferrara P: Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor α chain. J Biol Chem 1996;271:16921–16926.
  29. Feng N, Lugli SM, Schnyder B, Gauchat JF, Graber P, Schlagenhauf E, Schnarr B, Wiederkehr-Adam M, Duschl A, Heim MH, Lutz RA, Moser R: The interleukin-4/interleukin-13 receptor of human synovial fibroblasts: Overexpression of the nonsignaling interleukin-13 receptor alpha2. Lab Invest 1998;78:591–602.
  30. Kawakami K, Taguchi J, Murata T, Puri RK: The interleukin-13 receptor alpha2 chain: An essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 2001;97:2673–2679.
  31. Leonard WJ, O’Shea JJ: JAKs and STATs: Biological implications. Annu Rev Immunol 1998;16:293–322.
  32. Wurster AL, Tanaka T, Grusby MJ: The biology of Stat4 and Stat6. Oncogene 2000;19:2577–2584.
  33. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, Nakanishi K, Yoshida N, Kishimoto T, Akira S: Essential role of Stat6 in IL-4 signalling. Nature 1996;380:627–630.
  34. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA, Doherty PC, Grosveld G, Paul WE, Ihle JN: Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996;380:630–633.
  35. Takeda K, Kamanaka M, Tanaka T, Kishimoto T, Akira S: Impaired IL-13-mediated functions of macrophages in STAT6-deficient mice. J Immunol 1996;157:3220–3222.
  36. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, Mak TW: Signal transducer and activator of transcription (STAT)6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood, in press.
  37. Ohshima K, Akaiwa M, Umeshita R, Suzumiya J, Izuhara K, Kikuchi M: Interleukin-13 and interleukin-13 receptor in Hodgkin’s disease: Possible autocrine mechanism and involvement in fibrosis. Histopathology 2001;38:368–375.

    External Resources

  38. Bowman T, Garcia R, Turkson J, Jove R: STATs in oncogenesis. Oncogene 2000;19:2474–2488.
  39. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G, Stein H: Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin’s disease. Blood 1996;87:2918–2929.
  40. Dukers DF, Jaspars LH, Vos W, Oudejans JJ, Hayes D, Cillessen S, Middeldorp JM, Meijer CJ: Quantitative immunohistochemical analysis of cytokine profiles in Epstein-Barr virus-positive and -negative cases of Hodgkin’s disease. J Pathol 2000;190:143–149.
  41. Chen XP, Losman JA, Rothman P: SOCS proteins, regulators of intracellular signaling. Immunity 2000;13:287–290.

    External Resources

  42. Teruya-Feldstein J, Jaffe ES, Burd PR, Kingma DW, Setsuda JE, Tosato G: Differential chemokine expression in tissues involved by Hodgkin’s disease: Direct correlation of eotaxin expression and tissue eosinophilia. Blood 1999;93:2463–2470.
  43. van den Berg A, Visser L, Poppema S: High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltrate in Hodgkin’s lymphoma. Am J Pathol 1999;154:1685–1691.
  44. Jundt F, Anagnostopoulos I, Bommert K, Emmerich F, Muller G, Foss HD, Royer HD, Stein H, Dorken B: Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999;94:2065–2071.
  45. Sekiya T, Miyamasu M, Imanishi M, Yamada H, Nakajima T, Yamaguchi M, Fujisawa T, Pawankar R, Sano Y, Ohta K, Ishii A, Morita Y, Yamamoto K, Matsushima K, Yoshie O, Hirai K: Inducible expression of a Th2-type CC chemokine thymus- and activation-regulated chemokine by human bronchial epithelial cells. J Immunol 2000;165:2205–2213.
  46. Mathew A, MacLean JA, DeHaan E, Tager AM, Green FH, Luster AD: Signal transducer and activator of transcription 6 controls chemokine production and T helper cell type 2 cell trafficking in allergic pulmonary inflammation. J Exp Med 2001;193:1087–1096.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50